
|Articles|December 6, 2012
Bigger Role Seen for Breast Cancer Drug
Advertisement
The widely prescribed drug tamoxifen already plays a major role in reducing the risk of death from breast cancer. But a new study suggests that women should be taking the drug for twice as long as is now customary, a finding that could upend the standard that has been in place for about 15 years.
In the study, patients who continued taking tamoxifen for 10 years were less likely to have the cancer come back or to die from the disease than women who took the drug for only five years, the current standard of care.
Read the full story:
Source: The New York Times
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
Primary Care Capacity Gaps Threaten Respiratory Prevention
3
COPERNICOS Trial: Eosinophil-Guided ICS Reduction Safe in COPD, Vestbo Says
4
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
5




